HOME >> MEDICINE >> NEWS
Interferons for treatment of SARS?

Authors of a research letter in this week's issue of THE LANCET suggest that recombinant interferons - synthetic versions of naturally occurring compounds of the immune system - could be a an effective treatment for Severe Acute Respiratory Syndrome (SARS).

Although antivirals are probably essential for the treatment of SARS-CoV infection, the antiviral ribavirin (a conventional treatment for SARS) is not always effective. Jindrich Cinatl from Frankfurt University Medical School, Germany, and colleagues assessed the antiviral potential of recombinant interferons against two strains of the SARS coronavirus (SARS-CoV) analysed in Frankfurt and Hong Kong. The investigators replicated the virus in two cell lines in a laboratory setting.

Interferon beta was effective in the two cell lines; interferon alpha effectively inhibited SARS-CoV replication, but with a sensitivity index 50-90 times lower than that for interferon beta. Interferon gamma was slightly better than interferon alpha in one of the cell lines, but was completely ineffective in the other cell line.

Jindrich Cinatl comments: "We showed that interferons inhibit SARS-CoV replication in vitro. Interferon beta was most potent, showing prophylactic protection and antiviral potential after infection. Interferon beta could be the drug of choice, alone or in combination with other antiviral drugs, in the treatment of SARS."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
24-Jul-2003


Page: 1

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Chronic pain treatments more effective when taken together, new study shows
3. Brain activity prior to treatment flags vulnerability to antidepressant side effects
4. Cultural and social factors influence prostate cancer treatment
5. Research offers hope of new treatments for liver damage
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Stanford patient is first to test new treatment for peripheral arterial disease
8. Scientist works on innovative treatments for brain tumors
9. Blacks less likely to get expensive, newer heart treatments
10. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
11. Study examines lessons learned at Africas first public antiretroviral treatment clinic

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Interferons for treatment SARS

(Date:5/4/2015)... Malibu, CA (PRWEB) May 04, 2015 ... of KissSafe™ oral antiseptic breath spray. KissSafe™ is ... making kissing a safer experience while adding fresh ... that safely and effectively kills germs in the ... kissing. It also contains ingredients that possess additional ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Leonardo J. ... and chief physician executive, and William C. Daniel, M.D., ... and accepted personal invitations from the Secretary of the ... Forum (NSF) at the Air War College, Maxwell Air ... expose influential citizens to senior U.S. and international officers ...
(Date:5/4/2015)... 04, 2015 The University of ... launched a new initiative at UC Davis School ... of physicians committed to advancing Latino health. , ... or Preparing Students to Be Physicians, (“Prep Médico” ... provide scholarships, mentorship and internship opportunities, a residential ...
(Date:5/4/2015)... 2015 Takeda Pharmaceuticals Corp. has agreed ... thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) that ... that a patient will develop bladder cancer. According ... of those eligible for the Actos settlement accept its ... cases currently pending in courts around the country, including ...
(Date:5/4/2015)... 04, 2015 McNeil & Company ... the expansion of coverage for its Emergency Services ... of industry-tailored insurance and proactive risk management to the ... are dedicated to providing our customers with unparalleled service ... evolving needs. We are excited to launch over 100 ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
(Date:5/4/2015)... SAN DIEGO , May 4, 2015 /PRNewswire/ ... an oncology company focused on the clinical development ... pre-clinical data showing mitochondria-specific effects of the Company,s ... significantly enhanced anti-tumor activity when combined with a ... study found ME-344 to be a potent inhibitor ...
(Date:5/4/2015)... , May 4, 2015  FireflySci Inc., the newest member of the cuvette ... launch, they have turned the cuvette industry on its head by offering scientists amazing support for ... Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... , May 4, 2015 Dyadic International, ... whose patented and proprietary technologies are used to ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... its financial results for quarter ending March 31, ... 2015 and will host a conference call that ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
Cached News: